AQR Capital Management
JNCE

AQR Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

AQR Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-34,981
Closed -$106K – 2371
2022
Q2 		$106K Sell
34,981
-56,290
-62% -$274K ﹤0.01% 2084
2022
Q1 		$620K Sell
91,271
-70,155
-43% -$500K ﹤0.01% 1735
2021
Q4 		$1.35M Sell
161,426
-5,766
-3% -$47.5K ﹤0.01% 1406
2021
Q3 		$1.24M Buy
167,192
+11,240
+7% +$69.6K ﹤0.01% 1431
2021
Q2 		$1.06M Buy
155,952
+7,657
+5% +$63.6K ﹤0.01% 1559
2021
Q1 		$1.52M Sell
148,295
-48,363
-25% -$530K ﹤0.01% 1361
2020
Q4 		$1.38M Sell
196,658
-6,078
-3% -$47.3K ﹤0.01% 1353
2020
Q3 		$1.65M Sell
202,736
-251,738
-55% -$1.56M ﹤0.01% 1198
2020
Q2 		$3.14M Sell
454,474
-168,021
-27% -$906K 0.01% 960
2020
Q1 		$2.96M Buy
+622,495
New +$3.58M 0.01% 946
2019
Q3 		– Sell
-288,422
Closed -$1.43M – 2190
2019
Q2 		$1.43M Sell
288,422
-98,753
-26% -$524K ﹤0.01% 1375
2019
Q1 		$2.4M Buy
387,175
+255,732
+195% +$1.24M ﹤0.01% 1245
2018
Q4 		$443K Buy
+131,443
New +$614K ﹤0.01% 1821

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

AQR Capital Management's JNCE Position: Q3 2022 in Review

AQR Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2022, closing a stake of 34,981 shares — an estimated $106K sold.

AQR Capital Management first reported a position in JNCE in Q4 2018 and held it in 13 quarters. The position peaked at $3.14M in Q2 2020. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

  • AQR Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • AQR Capital Management sold 34,981 Jounce Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $106K.
  • AQR Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2018 and held it in 13 quarters.
  • AQR Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $3.14M in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on AQR Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.